FG-B902

N/A

Report date: 2025/06/11 10:17:26

Base Information

Drug NameFG-B902
Drug Alias NameBispecific PVRIG check point inhibitor/TIGIT check point inhibitor (FutureGen Biopharm)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTransmembrane protein PVRIG modulatorsT lymphocytes stimulantsT cell immunoglobulin and ITIM domains modulators +[4] 
TargetsT cell immunoglobulin and ITIM domainsTransmembrane protein PVRIG
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesFutureGen Biopharm (Beijing) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFutureGen Biopharm (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A